Results 21 to 30 of about 21,210 (293)
Micafungin: a sulfated echinocandin [PDF]
The Journal of Antibiotics, 2009 AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Seiji Hashimoto
openalex +4 more sources
Comparison of echinocandin antifungals
Therapeutics and Clinical Risk Management, 2007 The incidence of invasive fungal infections, especially those due to Aspergillus spp. and Candida spp., continues to increase. Despite advances in medical practice, the associated mortality from these infections continues to be substantial. The echinocandin antifungals provide clinicians with another treatment option for serious fungal infections ...
Gregory Eschenauer +2 more
openalex +5 more sources
Fungal echinocandin resistance [PDF]
Fungal Genetics and Biology, 2010 The echinocandins are the newest class of antifungal agents in the clinical armory. These secondary metabolites are non-competitive inhibitors of the synthesis of beta-(1,3)-glucan, a major structural component of the fungal cell wall. Recent work has shown that spontaneous mutations can arise in two hot spot regions of Fks1 the target protein of ...
Neil A. R. Gow +2 more
openaire +6 more sources
Echinocandin Resistance in Candida [PDF]
Clinical Infectious Diseases, 2015 Invasive fungal infections are an important infection concern for patients with underlying immunosuppression. Antifungal therapy is a critical component of patient care, but therapeutic choices are limited due to few drug classes. Antifungal resistance, especially among Candida species, aggravates the problem.
David S. Perlin
openalex +4 more sources
Echinocandins – structure, mechanism of action and use in antifungal therapy
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 With increasing number of immunocompromised patients as well as drug resistance in fungi, the risk of fatal fungal infections in humans increases as well.
Mateusz Szymański +4 more
semanticscholar +1 more source
In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris
Antibiotics, 2021 Candida auris is an emergent fungal pathogen that causes severe infectious outbreaks globally. The public health concern when dealing with this pathogen is mainly due to reduced susceptibility to current antifungal drugs.
Unai Caballero +6 more
semanticscholar +1 more source
Candida vulturna, the Next Fungal Menace? A Narrative Review. [PDF]
MycosesABSTRACT Introduction The yeast Candida vulturna is a member of the Candida haemulonii species complex, like its close relative Candida auris. Members of this species complex, including C. vulturna, often display reduced susceptibility to one or more antifungal classes. Human invasive infections by C.
Harchand R +5 more
europepmc +2 more sources
Micafungin: A New Echinocandin [PDF]
Clinical Infectious Diseases, 2006 Micafungin, a potent inhibitor of 1,3-beta-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for use in clinical practice. This agent shares with caspofungin an identical spectrum of in vitro activity against Candida albicans, non-albicans species of Candida, and Aspergillus species, as well as several
Jack D. Sobel +1 more
openaire +3 more sources
Echinocandins: structural diversity, biosynthesis, and development of antimycotics
Applied Microbiology and Biotechnology, 2020 Echinocandins are a clinically important class of non-ribosomal antifungal lipopeptides produced by filamentous fungi. Due to their complex structure, which is characterized by numerous hydroxylated non-proteinogenic amino acids, echinocandin antifungal ...
Wolfgang Hüttel
semanticscholar +1 more source
Some issues of the resistance of Candida glabrata to echinocandins [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2019 Invasive candidiasis is a common, severe and often difficult to treat complication in various categories of patients. Despite the fact that in most cases Candida albicans retains a leading position as an etiological cause, a pathogen such as Candida ...
Veselov A.V.
doaj +1 more source